QMPSB is an arylsulfonamide-based

synthetic cannabinoid Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids ( THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synthe ...

that has been sold as a

designer drug A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. D ...

. QMPSB was first discovered by Nathalie Lambeng and colleagues in 2007. It acts as a full

agonist An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ag ...

of the CB₁ receptor and CB₂ receptor with K_i values of 3 nM and 4 nM, respectively. Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB₂ receptor. This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004. The quinolin-8-yl ester motif of QMPSB led to the discovery of other designer cannabinoids such as

PB-22 PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represent ...

and BB-22.

References

Arylsulfonamides Cannabinoids Designer drugs 1-Piperidinyl compounds Quinolines {{cannabinoid-stub

See also

References